You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Pfizer is the first drugmaker to join the Strata PATH platform trial and will contribute drugs to advanced cancer patients in four study arms.
The company is working to expand access to its liquid biopsy assay outside of the US, after receiving US Food and Drug Administration approval last year.
The test uses a technology called Switch-Blocker that is co-owned by the companies and enables both viral detection and strain discrimination.
The new service, slated for launch in the second half of 2021, will allow Myriad to expand its cancer tumor profiling services.
The test uses prognostic markers to group women based on their risk of 10-year recurrence of ductal carcinoma in situ.
The investment bank said that Lucira's COVID-19 single-use test could have widespread use with potential for adoption in the over-the-counter markets.
Under the deal, expected to close in April, Agilent will pay $550 million in cash on closing and up to an additional $145 million based on future milestones.
The RT-PCR-based test is designed to detect three SARS-CoV-2 genes in saliva samples collected in the presence of a trained observer.
The firm attributed its quarterly and annual revenue gains primarily to sales of COVID-19 testing sample collection devices.
A UCLA-led team uncovered differences in DNA methylation patterns between patients with persistent and resolving methicillin-resistant Staphylococcus aureus infections.
The liquid biopsy method analyzes fragment ends within recurrently protected regions in cell-free DNA from a patient's urine sample.
Azova's kit is for use with Fluidigm's Advanta Dx SARS-CoV-2 RT-PCR assay, an extraction-free, saliva-based COVID test that previously received EUA.
The company also said that it had received EUA from the US Food and Drug Administration for a non-prescription version of its COVID-19 sample collection kit.
The company's cartridge for pneumonia for the Unyvero system is under review and pending approval by Chinese regulators.
Bio-Techne's CEO said the coverage decision will expand access to its EPI test and enable additional men to better decide whether to proceed with a prostate biopsy.
Hologic said that the transaction further strengthens its molecular diagnostics business by expanding its international capabilities, among other benefits.
The firm said it is currently also developing Novodiag Resp-4, a molecular test for the rapid, on-demand detection of the viruses.
The firm said it is drawing up plans for its business in a post-pandemic world, planning the introduction of new testing panels and enhancing its respiratory panel.
During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.
The company doesn’t expect significant revenue from the test this year, but executives said that they are already seeing positive reception trends.
Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.
The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.
Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.
In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.